Sysmex (OTCMKTS:SSMXY) Shares Gap Up on Earnings Beat

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $10.94, but opened at $12.1755. Sysmex shares last traded at $12.5150, with a volume of 7,343 shares trading hands.

The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The company had revenue of $825.85 million for the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Sysmex Trading Up 14.4%

The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The firm has a market cap of $7.88 billion, a PE ratio of 29.80 and a beta of 1.05. The company’s 50 day moving average price is $9.38 and its two-hundred day moving average price is $9.07.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.